Sagramostim

DRUG2 trials

Sponsors

University of Colorado, Denver, Vestre Viken Hospital Trust

Conditions

Alzheimer's DiseaseNSCLC Stage IVNSCLC, Stage IIIOncology

Phase 2

Study of the Safety & Efficacy of Leukine® in the Treatment of Alzheimer's Disease

CompletedNCT01409915

University of Colorado, DenverAlzheimer's Disease

Start: 2011-03-31End: 2019-12-09Updated: 2021-06-02

Efficacy and Safety of Anti-PD-1/PD-L1 Treatment +/- UV1 Vaccination in Patients With Non-small Cell Lung Cancer

RecruitingNCT05344209

Vestre Viken Hospital TrustNSCLC, Stage III, NSCLC Stage IV, Oncology

Start: 2022-08-12End: 2027-07-01Target: 138Updated: 2023-11-09

Related Papers

Tolerability and efficacy of the cancer vaccine UV1 in patients with recurrent or metastatic PD-L1 positive head and neck squamous cell carcinoma planned for first-line treatment with pembrolizumab – the randomized phase 2 FOCUS trial

Frontiers in Oncology2024-02-0711 citations

156TiP The LUNGVAC-study: A randomized phase II, open-label, multicenter study investigating efficacy and safety of anti-PD-1/PD-L1 treatment +/- UV1 vaccination as first-line treatment in patients with inoperable advanced or metastatic non-small cell lung cancer (NSCLC)

Immuno-Oncology Technology2023-12-01

GM‐CSF reduces amylin amyloid, inhibits pancreatic apoptosis, and sustains lowered blood glucose levels in the hIAPP mouse model of Type 2 diabetes mellitus, a known risk factor for Alzheimer’s disease

Alzheimer s & Dementia2023-12-01

The Potential Alzheimer’s Disease Drug, GM‐CSF, Enhances the Anti‐Viral Immune Response and Reduces Mortality in a Mouse Model of COVID‐19

Alzheimer s & Dementia2022-12-01

GM‐CSF reduces amylin amyloid and prevents pancreatic cell death in the hIAPP mouse model of Type 2 diabetes mellitus, a known risk factor for Alzheimer’s disease

Alzheimer s & Dementia2022-12-01

Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination.

2022-09-1117 citations

Safety and efficacy of sargramostim (GM‐CSF) in the treatment of Alzheimer's disease

Alzheimer s & Dementia Translational Research & Clinical Interventions2021-01-0187 citations

Double‐blind placebo‐controlled trial of the safety and efficacy of GM‐CSF/sargramostim in subjects with mild‐to‐moderate Alzheimer’s disease

Alzheimer s & Dementia2020-12-01

A multiancestry analysis of Alzheimer’s disease coexpressed gene networks identifies a common immune signaling pathway regulated by granulocyte‐colony stimulating factor (G‐CSF)

Alzheimer s & Dementia2020-12-01